Chemomab Therapeutics Ltd.
CMMBHealthcare|Biotechnology|IL
$1.32
+0.07 (+5.60%)
DCF Value
$1.56
Tangible Book / Share
$1.09
Cash / Share
$0.84
About
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
Stock Price
-48.8%(1Y)
1M
-5.0%
3M
-31.6%
6M
-25.4%
YTD
-20.0%
1Y
-51.1%
3Y
-48.4%
5Y
-96.7%
Pipeline Summary
6 total trials3
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
Suspended: 1Completed: 5
Key Facts
Market Cap$8.9M
Employees37 (+85% YoY)
CEOAdi Mor George
IPO DateFeb 12, 2019
Beta0.66
52-Week Range$0.92 – $2.99
Avg Volume141,217
ExchangeNASDAQ
Websitechemomab.com
Ownership
Float88.6%
Shares Outstanding6.8M
Recent Insider Trades
Cohen Neil HarrisSELL
Aug 27, 20261,304 shares @ $2.85
Cohen Neil HarrisSELL
Aug 28, 20261,000 shares @ $2.80
Cohen Neil HarrisAWARD
Mar 16, 20265,172 shares @ $2.14
Cohen Neil HarrisAWARD
Mar 16, 20253,821 shares @ $6.16
Cohen Neil HarrisAWARD
Mar 18, 20242,520 shares @ $2.96
Peers
Recent News
Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective
Nov 2, 2026 · globenewswire.com
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
Aug 31, 2026 · globenewswire.com
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 19, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:02 AM